Correlation of the topographical arrangement and the functional pattern of tissue-infiltrating macrophages in giant cell arteritis.

End organ ischemia, fragmentation of elastic membranes, and aneurysm formation in patients with giant cell vasculitis results from an inflammation destroying the mural layers of large and medium sized arteries. Although the inflammatory infiltrate extends through all layers of the affected blood vessel, the most pronounced changes involve the intima and the internal elastic lamina. Analysis of the functional profile of tissue infiltrating CD68+ cells demonstrates that different subsets of macrophages can be distinguished. TGFbeta1-expressing CD68+ cells coproduce IL-1beta and IL-6, are negative for inducible nitric oxide synthase (iNOS), and exhibit a strong preference for localization in the adventitia. The adventitial homing of TGFbeta1+ CD68+ cells places them in the vicinity of IFN-gamma secreting CD4+ T cells which also accumulate in the exterior layer of the artery. Conversely, iNOS expressing CD68+ cells are negative for TGFbeta and are almost exclusively found in the intimal layer of the inflamed artery. The intimal-medial junction is the preferred site for 72-kD collagenase expressing CD68+ cells. Thus, TGFbeta1-producing macrophages colocalize with activated CD4+ T cells and home to an area of inflammation which is distant from the site of tissue damage but critical in regulating cellular influx, suggesting that TGFbeta1 functions as a proinflammatory mediator in this disease. iNOS- and 72-kD collagenase-producing macrophages accumulate at the center of pathology implying a role of these products in tissue destruction. These data indicate that the microenvironment controls the topographical arrangement as well as the functional commitment of macrophages.

[1]  C. Weyand,et al.  Giant cell arteritis as an antigen-driven disease. , 1995, Rheumatic diseases clinics of North America.

[2]  H. Gresham,et al.  Spontaneous elaboration of transforming growth factor beta suppresses host defense against bacterial infection in autoimmune MRL/lpr mice , 1994, The Journal of experimental medicine.

[3]  G. Hunder,et al.  Polymyalgia rheumatica: a 10-year epidemiologic and clinical study. , 1982, Annals of internal medicine.

[4]  S. Abramson,et al.  Nitric Oxide: A Novel Mediator of Inflammation , 1995, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[5]  U. Oppitz,et al.  Distinct vascular lesions in giant cell arteritis share identical T cell clonotypes , 1994, The Journal of experimental medicine.

[6]  C. Weyand,et al.  Interferon-gamma-producing T cells in giant cell vasculitis represent a minority of tissue-infiltrating cells and are located distant from the site of pathology. , 1996, The American journal of pathology.

[7]  G. Hunder,et al.  Tissue Cytokine Patterns in Patients with Polymyalgia Rheumatica and Giant Cell Arteritis , 1994, Annals of Internal Medicine.

[8]  E. Campo,et al.  IMMUNOHISTOCHEMICAL ANALYSIS OF LYMPHOID AND MACROPHAGE CELL SUBSETS AND THEIR IMMUNOLOGIC ACTIVATION MARKERS IN TEMPORAL ARTERITIS: Influence of Corticosteroid Treatment , 1989, Arthritis and rheumatism.

[9]  S. Wahl,et al.  Rapid onset synovial inflammation and hyperplasia induced by transforming growth factor beta , 1990, The Journal of experimental medicine.

[10]  S. Reed,et al.  Transforming growth factor-beta in leishmanial infection: a parasite escape mechanism. , 1992, Science.

[11]  L M Wakefield,et al.  Transforming growth factor type beta induces monocyte chemotaxis and growth factor production. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[12]  T. M. Doherty T-cell regulation of macrophage function. , 1995, Current opinion in immunology.

[13]  T. Taniguchi,et al.  The IL-2 receptor complex: its structure, function, and target genes. , 1993, Annual review of immunology.

[14]  S. Wahl,et al.  Transforming growth factor beta: the good, the bad, and the ugly , 1994, The Journal of experimental medicine.

[15]  M. Sporn,et al.  The Transforming Growth Factor‐Betas: Past, Present, and Future , 1990, Annals of the New York Academy of Sciences.

[16]  A. Brack,et al.  Disease patterns and tissue cytokine profiles in giant cell arteritis. , 1997, Arthritis and rheumatism.

[17]  G. Hunder,et al.  Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. , 1993, Arthritis and rheumatism.

[18]  G. Dusting Nitric oxide in cardiovascular disorders. , 1995, Journal of vascular research.

[19]  S. Wahl,et al.  Reversal of acute and chronic synovial inflammation by anti- transforming growth factor beta , 1993, The Journal of experimental medicine.

[20]  M. Sporn,et al.  TGF-β: Regulation of extracellular matrix , 1992 .

[21]  M. Sporn,et al.  TGF-beta: regulation of extracellular matrix. , 1992, Kidney international.

[22]  S. Singer,et al.  The specific direct interaction of helper T cells and antigen- presenting B cells. II. Reorientation of the microtubule organizing center and reorganization of the membrane-associated cytoskeleton inside the bound helper T cells , 1987, The Journal of experimental medicine.

[23]  Y. Vodovotz,et al.  Mechanisms of suppression of macrophage nitric oxide release by transforming growth factor beta , 1993, The Journal of experimental medicine.

[24]  J. Goronzy,et al.  Functional profile of tissue-infiltrating and circulating CD68+ cells in giant cell arteritis. Evidence for two components of the disease. , 1994, The Journal of clinical investigation.

[25]  S. Abramson,et al.  Modulation of human T cell responses by nitric oxide and its derivative, S-nitrosoglutathione. , 1993, Arthritis and rheumatism.

[26]  D A Bloch,et al.  The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. , 2010, Arthritis and rheumatism.